IASO Bio and Innovent Present New Data of FUCASO® (Eque

/PRNewswire/ -- IASO biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell...

Related Keywords

Shanghai , China , Peking , Beijing , United States , Nanjing , Jiangsu , Tongji , Sichuan , Huazhong , Hubei , Chinese , American , Chunrui Li , Jue Wang , Innovent Biologics , Equecabtagene Autoleucel , Adimab Incyte , Eli Lilly , Innovent Biologics Inc , Union Medical College , China National Medical Products Administration , Huazhong University Of Science Technology , American Society Of Hematology , Md Anderson Cancer Center , Tongji Medical College , Chinese Academy Of Medical Sciences , Institute Of Hematology , American Society , Efficacy Outcomes , Multiple Myeloma , San Diego , Associate Professor , Tongji Hospital , Huazhong University , Professor Lu Gui Qiu , Blood Diseases Hospital , Chinese Academy , Medical Sciences , Peking Union Medical College , New Drug Application , National Medical Products Administration , Sintilimab Injection , Bevacizumab Injection , Adalimumab Injection , Rituximab Injection , Pemigatinib Oral Inhibitor , Ramucirumab Injection , Selpercatinib Capsules , Autoleucel Injection , Tafolecimab Injection , Cancer Center ,